ARAY Accuray Cyberknife Robotic RadioSurgery Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARAY Accuray Cyberknife Robotic RadioSurgery

ARAY 1.480

-4.8%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	1/24/2018 10:24:38 AM
	of 94

Reports Q2 (Dec) loss of $(0.06) per share, $0.05 better than the Capital IQ Consensus of ($0.11); revenues rose 14.7% year/year to $100.33 mln vs the $90.31 mln Capital IQ Consensus. Product revenue totaled $47.1 mln, up 33% YoY. Co reaffirms guidance for FY18, sees FY18 revs of $390-400 mln vs. $396.1 mln Capital IQ Consensus Estimate. Co reaffirms adjusted EBITDA guidance of $25-30 mln. "Our 33 percent year-over-year product revenue growth during the second quarter was primarily driven by solid implementation of our strategies to improve distributor order to revenue conversion and increased Radixact contribution. As the fiscal year progresses, we believe that we will see the initial signs of commercial momentum in the U.S., which could enable us to expand our growth rate in fiscal 2019. We are building this momentum through the market's increased recognition of the clinical benefits of our radiation therapy solutions."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next